Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

AJCC8 and ESMO 2024 melanoma SLNB guidance interpreter

A deterministic staging-and-guidance lookup, not a nodal-positivity calculator.

Evidence-based context for fast calculator use

Purpose:
Identify the AJCC8 primary T category and its source-specific ESMO SLNB guidance disposition.
Population:
Adults with primary invasive cutaneous melanoma, initial pretreatment, cN0, no regional nonnodal disease, and M0.
Factors:
Breslow thickness/reliability, ulceration, mitotic rate, deep margin, clinical disease scope
Reference:
Gershenwald et al. CA Cancer J Clin. 2017;67:472-492. ESMO Cutaneous Melanoma CPG, Ann Oncol. 2025;36:10-30.
HomeMelanoma SLNB Guidance Interpreter, AJCC8 and ESMO 2024
Pin your most used calculators here by clicking the star in the dropdown.

Melanoma SLNB Guidance Interpreter, AJCC8 and ESMO 2024

Optional
mm

Optional only when Breslow thickness cannot be reliably determined.

Optional
/mm2

Optional unless the pT1a special-discussion branch is being assessed.

Optional

Optional unless the pT1a special-discussion branch is being assessed.

Clinical Context & Background

This source-specific interpreter assigns the AJCC8 cutaneous melanoma primary-tumor category from an externally reported reliable Breslow thickness and ulceration, or pTx when thickness cannot be reliably determined. It then identifies the corresponding ESMO 2024 SLNB guidance category for adults with primary invasive cutaneous melanoma at initial pretreatment cN0, M0 assessment without microsatellite, satellite, or in-transit disease. It is not for reassessment after SLNB already performed.
AJCC8 uses 0.8, 1.0, 2.0, and 4.0 mm boundaries without hidden rounding. Mitotic rate does not change the T category. ESMO identifies special pT1a situations when the mitotic rate is at least 3/mm2 or the deep margin is positive/transected, and also identifies pTx as a special-discussion setting.
This route does not estimate an individual probability, apply an NCCN model, nomogram or CP-GEP, use age as a risk multiplier, or recommend a procedure or treatment. ASCO/SSO 2018 is corroborative context, not a separate calculation.
Formula Logic
AJCC8 T-category decision tree followed by the matched ESMO 2024 SLNB guidance row; no probability model.

Reference Data

Source-defined categoryNeutral guidance interpretation
pT1a without specified special factorsNot routinely recommended category
pT1a with mitotic rate >=3/mm2 or positive/transected deep margin; pTxSpecial-case discussion may be considered
pT1bShould be discussed
cN0 pT2a or higherGuideline-recommended category

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Melanoma SLNB Guidance Interpreter, AJCC8 and ESMO 2024 when interprets an AJCC8 cutaneous-melanoma T category and the matched ESMO 2024 sentinel-lymph-node-biopsy guidance row without estimating nodal probability.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning pT1a without specified special factors through cN0 pT2a or higher.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm Breslow thickness, ulceration, mitotic/pathologic features, anatomic site, age, staging, and multidisciplinary context.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Sentinel-node probability does not replace AJCC staging or individualized surgical discussion.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with melanoma pathology being assessed at the decision point described by the model

How to apply this result

For a representative case, verify AJCC8-reported Breslow thickness, Pathologist-reported ulceration, Pathologist-reported mitotic rate, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Calculation verification history

Verified

  1. : Production browser revalidation

    • Three source-backed cases passed through visible production controls at pT1a special-factor, exact 0.8 mm pT1b, and involved-node Outside scope branches.
    • The involved-node disposition now retains a source-specific guidance-not-assigned receipt without the former generic invalid-input contradiction.
    • No unexpected N/A, stale control, literal undefined/null value, or browser-console error was observed.
    Download latest production check (Excel)

    Case-level evidence is retained in validation/browser-revalidation/melanoma-sentinel-lymph-node-biopsy-2026-08-03.json.

  2. : Outside-scope receipt corrected and browser-revalidated locally

    • Clinically or radiologically involved nodes now produce an authored Outside scope receipt with guidance not assigned instead of the contradictory generic missing-or-invalid-input trace.
    • Ten visible-browser cases passed across 11 Calculate submissions, covering all AJCC8 thickness boundaries, ulceration branches, the pT1a mitotic special factor, pTx, intentional outside scope, and reset/repeat behavior.
    • The independent source audit remains 2048/2048 with zero maximum absolute difference; production revalidation remains pending deployment.

    Case-level local remediation evidence is retained in validation/browser-production/melanoma-sentinel-lymph-node-biopsy.local-remediation.json; the original production finding remains retained separately.

  3. : Production browser validation found an outside-scope trace defect

    • All ten AJCC8 T-category and ESMO guidance calculations or dispositions matched the source-backed oracle across 11 visible Calculate attempts.
    • The matrix covered every raw thickness boundary, ulceration suffixes, the pT1a mitotic special factor, pTx, outside-scope cN disease, and reset/repeat behavior.
    • One UI case failed because a fully completed cN-involved profile correctly labeled Outside scope simultaneously displayed Required input is missing or invalid in its trace; production also emitted React hydration error #418.

    Case-level production evidence is retained in validation/browser-production/melanoma-sentinel-lymph-node-biopsy.json.

  4. : Input workflow simplified and revalidated

    • Reduced the public form to result-, branch-, unit-, and applicability-changing inputs; removed or consolidated non-scoring, administrative, and duplicate questions.
    • Preserved the verified calculation or report-interpretation logic, thresholds, model version, component logic, and supported result pathways behind strict deterministic adapters.
    • Passed the calculator-specific regression audit, adapter-parity and malformed-input checks, the 144-calculator input-quality audit, and the 43-calculator entry-burden audit.

  5. : Identity corrected

    • Reframed the route as an AJCC8 T-category and ESMO 2024 SLNB guidance interpreter rather than an unsupported nodal-positivity model.
    • Removed NCCN-version, age-multiplier, probability, nomogram, CP-GEP, and treatment identities.

  6. : Logic and contract corrected

    • Implemented exact AJCC8 0.8, 1.0, 2.0, and 4.0 mm boundaries, pTx, ulceration suffixes, and source-specific ESMO pT1a/pT1b/T2a+ guidance rows.
    • Replaced defaults and coercion with an exact immutable 12-key applicability contract and deterministic trace.

  7. : Full validation completed

    • 2048/2048 deterministic assertions passed against a separately encoded literal oracle.
    • This is software implementation verification, not prospective or independent clinical validation and not procedural advice.

Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.

Found a possible issue? Report it to improve this calculator

Share This Calculator

Share:

Popular Tools

Myeloma R2-ISS and IMWG Frailty PanelFebrile Neutropenia TriagePalliative Survival Prediction

Frequently Asked Questions

Does this calculate the chance of a positive sentinel node?

No. It returns no probability, multiplier, benefit estimate, nomogram output, or risk gauge. It only interprets the AJCC8 T category and source-specific ESMO guidance row.

Does mitotic rate change AJCC8 T category?

No. AJCC8 removed mitotic rate as a T1 staging criterion. ESMO uses a rate of at least 3/mm2 only as one special-case discussion factor for pT1a.

What does pTx mean here?

pTx is returned only when Breslow thickness cannot be reliably determined and the numeric Breslow field is null. ESMO lists that setting for special-case discussion; this is not procedural advice.

Evidence-based oncology decision support. Verify with clinical guidelines.